SITC 2021 | ASPEN-03: evorpacept in combination with pembrolizumab in patients with advanced HNSCC

Jong Chul Park, MD, Harvard Medical School, Boston, MA, discusses ASPEN-03 (NCT04675294), an open-label, randomised Phase II study evaluating evorpacept (ALX148) plus pembrolizumab compared to pembrolizumab alone in patients with PD-L1+ head and neck squamous cell carcinoma (HNSCC) in the first-line setting. Primary endpoints for the trial are 12-month overall survival and objective response rate. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.